“a favorable trend”

Abstract Introduction The randomized phase III KEYNOTE-522 trial demonstrated that addition of pembrolizumab to neoadjuvant chemotherapy provided a significant improvement in event-free survival and a favorable trend in overall survival for high-risk early-stage triple-negative breast cancer (eTNBC).

Subgroup results differed by modality; linked color imaging showed a favorable trend, but superiority remains unproven.

In that study, the 3-year PFS rate was 66.3% in the group that received DOS therapy and 60.2% in the group that received surgery plus postoperative S-1 therapy, indicating a favorable trend for the preoperative group [ 9 ].

Conclusions: The engagement in physical activity during pregnancy exhibits a favorable trend in parameters associated with childhood overweight and obesity while presenting no adverse effects on such outcomes. pregnancy physical activity exercise childhood obesity This research received no external funding. pmc-status-qastatus 0 pmc-status-live yes pmc-status-embargo no pmc-status-released

They also find that there was no statistical difference in clinical improvement on the ODI, although a favorable trend in the rhBMP-2 group was found.

After adjusting for chemotherapy, relapse-free survival was longer in carriers than noncarriers in COQD (adjusted hazard ratio = 0.48 [95% CI = 0.26 to 0.87], P = .016), and a favorable trend was observed for other survival outcomes in both cohorts.

Conclusions In patients with HCM undergoing PVI for AF, PFA demonstrated a favorable trend toward a lower recurrence rate of atrial tachyarrhythmias at one-year follow-up compared to thermal ablation strategies.

This is a favorable trend in light of research demonstrating that support from spouses and family members during pregnancy and childbirth has a significant effect on pregnant women’s birth experiences [ 16 , 17 ].

4 Additionally, this meta‐analysis showed a favorable trend for COX‐2 inhibitors over NSAIDs and PPIs in reducing GI complications in the lower gut. 4 These results suggest that PPIs may not prevent mucosal damage in the mid‐ and lower gut.

After multivariable adjustment, the individualized PERT still showed a favorable trend for albumin, suggesting a potential nutritional pattern masked by the acute inflammatory response.

A favorable trend was observed in reducing intraoperative blood loss, though not statistically significant( P = 0.09).

Although this systematic review suggests a favorable trend for W&W, definitive conclusions must be drawn cautiously due to the clinical heterogeneity and variable methodologic quality of the included studies.

Nevertheless, the data suggests a favorable trend using this combination therapy ( Figure 3B ).

However, preliminary data suggest a favorable trend in the PD-1 and PD-1+VEGF groups compared to the Surg-only group.

The adsorption process of RB19 demonstrates a favorable trend under acidic conditions, primarily due to electrostatic attractions between the negatively charged functional groups of the anionic dye and the positively charged surface of the adsorbent.

Although not statistically significant, CTD‐PH patients showed a favorable trend with high‐risk patients decreasing from 20% to 10%.

After analyzing seven relevant studies, we found that, although a favorable trend towards high training volume exists (+20 sets per week per muscle group), there were no differences between moderate and high training volume responses for quadriceps femoris and biceps brachii hypertrophy.

Despite the high prevalence of dyslipidemia, obesity, and unhealthy lifestyle in Iran, lipid profile has a favorable trend.

The combination of two fractions of IR with anti-CTLA4 yielded a favorable trend in tumor growth delay compared to two-fraction IR with IgG, although it was not statistically significant (median days to endpoint: 13.5 Gy × 2 + anti-CTLA4 44 days, 13.5 Gy × 2 + IgG 41.5 days; Figure 4 d).

The EGFR L858R mutation showed a favorable trend in overall survival compared with the EGFR Ex19del mutation (not evaluated vs. 23.6 months).

In addition, neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab showed a favorable trend in event-free survival.

Over a mean follow-up of 4.4 ± 2.2 years, 137 patients (24.5%) experienced major adverse cardiovascular events, with FFR-CT use associated with a favorable trend toward risk reduction and a significant decrease in all-cause mortality [ 54 ].

It showed a favorable trend as they had a high overall LE, which also varied significantly according to the severity of the hemophilia, in line with therapeutic advances in the treatment of hemophilia.

Results demonstrated that the pembrolizumab plus lenvatinib arm achieved significantly prolonged median PFS compared with sunitinib monotherapy (23.9 months versus 9.2 months; HR 0.39; 95% CI, 0.32–0.49; p < 0.001), markedly improved ORR (71.0% versus 36.1%), and showed a favorable trend in median OS (HR 0.66), although median OS was not reached in either arm.

Although this subset of patients was diagnosed with dysplasia on x-ray, they showed a favorable trend of cartilage development.